Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2020

View Archived Issues

Homology initiates IND-enabling studies of novel gene therapy for Hunter syndrome

Feasibility trial of preoperative ipilimumab/nivolumab in locoregionally advanced urothelial cancer

Enrollment ongoing in phase I study of ALN-HSD

IAVI, Merck KGaA and Serum Institute of India collaborate to develop MAbs for COVID-19

Immutep announces investigator-initiated study of eftilagimod alpha in patients with COVID-19

Evgen Pharma receives all approvals to initiate STAR trial of SFX-01

Ultragenyx and Solid Biosciences collaborate to develop new gene therapies for DMD

First patient dosed in phase Ib/II study of dubermatinib plus decitabine in AML

Preclinical data presented for UB-612 vaccine against COVID-19

University of Central Florida patents new antimalarials

Janssen Pharmaceutica patent describes FFAR4 agonists

Anadolu Ueniversitesi discloses new compounds for cancer

Venenum Biodesign synthesizes TREX1 inhibitors

PhaseBio discontinues VANGARD study of pemziviptadil in patients with COVID-19

Hangzhou Sumgen Biotechnology discloses new fusion proteins for cancer immunotherapy

Phase III study of BiondVax's universal flu vaccine candidate M-001 does not meet primary endpoint

Targeting liver repair with an RSPO mimetic

LIDDS' NZ-TLR9 demonstrates antitumoral effect in mouse tumor models

KRAS G12C: Adagrasib holds its own at ENA 2020

Anelixis begins phase IIa study of AT-1501 in ALS

IDMC recommends continuation of phase III trial of REX-001 for diabetic CLI

Subcutaneous lirentelimab demonstrates sustained eosinophil suppression in phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...